Nephros (NEPH) Income from Continuing Operations (2010 - 2026)
Nephros (NEPH) posted Income from Continuing Operations of $1.2 million for Q2 2026, up 1097.0% on a QoQ basis from $100000.0 in Q1 2026, and up 405.06% year-over-year from $237000.0 in Q2 2025.
Powered by 
Analysis
Nephros (NEPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nephros has reported Income from Continuing Operations for 17 years, with the latest figure at $1.2 million in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 405.06% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $1.5 million, a 14.88% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 2447.5% from the prior year.
- Income from Continuing Operations was $1.2 million for Q2 2026 at Nephros, up from $100000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was $1.2 million in Q2 2026, with the low at -$1.6 million in Q1 2022.
- Average Income from Continuing Operations over 5 years is -$207666.7, with a median of -$200000.0 recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations sank 131.04% in 2025, then surged 405.06% in 2026.
- Over 5 years, Income from Continuing Operations stood at -$689000.0 in 2022, then decreased by 21.04% to -$834000.0 in 2023, then surged by 143.65% to $364000.0 in 2024, then slumped by 131.04% to -$113000.0 in 2025, then soared by 1159.29% to $1.2 million in 2026.
- The last three Income from Continuing Operations figures came in at $1.2 million (Q2 2026), $100000.0 (Q1 2026), and -$113000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 178.01 Bn | 172.41 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 131.29 Bn | 126.08 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 116.38 Bn | 107.56 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 106.01 Bn | 102.53 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 48.89 Bn | 44.64 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 32.59 Bn | 31.13 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 31.84 Bn | 29.89 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.61 Bn | 20.13 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Nephros | 48.31 Mn | 43.62 Mn | 4.03 Mn | 1.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -113,000.00 |
| Sep 30, 2025 | 337,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Dec 31, 2024 | 364,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | -208,000.00 |
| Dec 31, 2023 | -834,000.00 |
| Sep 30, 2023 | -192,000.00 |
| Jun 30, 2023 | -422,000.00 |
| Mar 31, 2023 | -295,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | -1.28 Mn |
| Jun 30, 2022 | -819,000.00 |
| Mar 31, 2022 | -1.55 Mn |
| Dec 31, 2021 | -726,000.00 |
| Sep 30, 2021 | -810,000.00 |